India’s government has signed a purchase order with vaccine producer Serum Institute for doses of the Oxford/AstraZeneca COVID-19 vaccine, a source familiar with the matter said on Monday.
Television channel CNBC-TV 18 said the order was for 11 million doses.
The government has also signed a purchase agreement with Indian firm Bharat Biotech for its COVID-19 vaccine, the news channel reported, citing unnamed sources.
Representatives for Serum, Bharat Biotech and India’s health ministry did not immediately respond to Reuters requests for comment.
India’s drug regulator had earlier this month given emergency use approval for both vaccines.
The government aims to secure 600 million doses for India’s vaccination drive that aims to inoculate 300 million citizens over the next six to eight months. The immunization programme is expected to begin on Jan. 16.
At nearly 10.5 million, India has the world’s second highest number of novel coronavirus infections behind the United States, although the country’s rate of increase in cases has been slowing.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.